Evaluating heart health in lung cancer patients receiving chemoradiotherapy
The Effect of Radiotherapy on the Heart in Loco-regional Advanced NSCLC Patients Treated With Definitive Radiotherapy Measured by Cardiac MR
This study looks at how chemoradiotherapy for lung cancer affects heart health in patients by monitoring their heart function before, during, and after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Odense University Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Odense C) |
| Trial ID | NCT05258448 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with loco-regional advanced non-small cell lung cancer (LA-NSCLC) who are undergoing curative treatment with chemoradiotherapy. Participants will be monitored for cardiac health through ECG and cardiac MRI before and for two years after their treatment to assess potential heart toxicity associated with the therapy. The study aims to document baseline cardiac conditions and track any structural changes or subclinical heart disease resulting from the treatment. By understanding these effects, the study seeks to improve patient management and outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with inoperable, histologically verified NSCLC who are planned for curative treatment.
Not a fit: Patients with operable devices like pacemakers or those who are claustrophobic may not benefit from this study due to contraindications for MRI.
Why it matters
Potential benefit: If successful, this study could lead to better monitoring and management of cardiac health in lung cancer patients undergoing chemoradiotherapy.
How similar studies have performed: While the investigation of cardiac toxicity in lung cancer treatments is gaining attention, this specific approach of long-term cardiac monitoring in this patient population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 Years * Inoperable and histologically/cytologically verified NSCLC. * Planned treatment with curative intent. * Capable of completing study procedures ECG and Cardiac MR. * Able of giving written and informed consent before study procedures are initiated. Exclusion Criteria: * Vulnerable patients. * Patients with operable devices as pacemaker/ICD and cochlear implant or other conditions where MR scan is contraindicated. * Claustrophobia.
Where this trial is running
Odense C
- Odense University Hospital — Odense C, Denmark (Recruiting)
Study contacts
- Principal investigator: Tine Schytte, Professor — Odense University Hospital
- Study coordinator: Agon AO Olloni, MD
- Email: agon.olloni@rsyd.dk
- Phone: 42206617
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.